Home › Companies › AMLX

Amylyx Pharmaceuticals, Inc.

AMLX Rare disease Lead: Phase 3 3 Biotech Distilled articles ↓

Metabolic Neurology Nucleic Acid Peptide Small Molecule

Most recent annual filing: 2026-03-03

Pipeline (5 active programs)

avexitide

Peptide Target: GLP-1 receptor

Post-Bariatric Hypoglycemia Phase 3 subcutaneous
Congenital Hyperinsulinism

sodium phenylbutyrate and taurursodiol

AMX0035

Small Molecule Target: endoplasmic reticulum stress, mitochondrial dysfunction

Wolfram Syndrome Phase 2 oral

AMX0114

Nucleic Acid Target: calpain-2, CAPN2

Amyotrophic Lateral Sclerosis Phase 1 intrathecal

AMX0318

Peptide Target: GLP-1 receptor

Post-Bariatric Hypoglycemia Preclinical Gubra A/S

Discontinued (1)

AMX0035 — Progressive Supranuclear Palsy · discontinued after discontinuation of AMX0035 for PSP

Biotech Distilled coverage (3)

2026-05-08 UPDATE: Amylyx Pharmaceuticals (AMLX) — The Quiet Tells Before the Binary 🔒 Paid
2026-03-28 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Clock Starts Now 🔒 Paid
2026-03-11 Amylyx Pharmacueticals (AMLX) - Scientific Deep Dive for Avexitide and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.